<DOC>
	<DOCNO>NCT02107872</DOCNO>
	<brief_summary>This phase 1 , randomize , double-blind , placebo-controlled , multiple ascend dose study assess safety , tolerability , pharmacokinetic ( PK ) , immunogenicity , pharmacodynamic ( PD ) effect REGN1500 patient metabolic disorder .</brief_summary>
	<brief_title>Study Assess Safety Tolerability Multiple Ascending Doses REGN1500</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Diseases</mesh_term>
	<criteria>Provide sign informed consent Otherwise healthy men woman age 18 65 year , inclusive Body mass index 18.0 kg/m2to 38.0 kg/m2 , inclusive Normal standard 12lead ECG Willing refrain consumption alcohol 24 hour prior study visit Willing consistently maintain his/her usual diet duration study Willing refrain strenuous exercise duration trial Willing able comply clinic visit studyrelated procedure For sexually active men woman childbearing potential , willingness utilize adequate contraception become pregnant ( partner [ ] become pregnant ) full duration study . Any clinically significant abnormality observe screen visit History drug alcohol abuse within 1 year screen Receipt another investigational drug therapy within 30 day least 5 halflives ( whichever longer ) , investigational drug prior screen visit . Significant concomitant illness history significant illness cardiac , renal , neurological , endocrinological , metabolic lymphatic disease , illness condition may adversely affect subject participation study Known history human immunodeficiency virus ( HIV ) antibody ; and/or positive hepatitis B surface antigen ( HBsAg ) , and/or positive hepatitis C antibody ( HCV ) screen visit Hospitalization reason within 60 day screen History presence malignancy within 5 year prior screen visit ( successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma , and/or localize carcinoma situ cervix Any medical psychiatric condition , opinion investigator , would place subject risk , interfere participation study interfere interpretation study result Any subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff directly involve conduct protocol , family member staff involve conduct protocol Pregnant breastfeed woman Note : The information list intend contain consideration relevant patient 's potential participation clinical trial inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>